Payment overview · 2025
General Payments
$725.67
42 reported records · 17 companies
Healthcare provider profile · identity verified
James M Orsini, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BELLEVILLE, NJ · NPI 1659516813
Verified facts
What the public records show
CMS Open Payments records show James M Orsini, M.D. received $725.67 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Imbruvica.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Imbruvica by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tecentriq as an associated drug or biological on 3585 records involving 2526 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Tecentriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.61 | 16.3% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $90.14 | 12.4% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $76.10 | 10.5% | 5 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $66.04 | 9.1% | 4 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $59.49 | 8.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $58.87 | 8.1% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $40.48 | 5.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.71 | 4.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $31.89 | 4.4% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $21.19 | 2.9% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $20.98 | 2.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $20.43 | 2.8% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $18.38 | 2.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.27 | 2.5% | 1 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $18.06 | 2.5% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $16.05 | 2.2% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $14.98 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $725.67 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $90.14 | 5 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $89.50 | 5 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $76.10 | 5 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $66.04 | 4 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $59.49 | 4 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $47.38 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $40.48 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
270 | 62 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Tecentriq open payments reported associated product |
CMS Open Payments — General Payments 3585 supporting records · 2526 recipient NPIs · example record 1211488420 |
Tecentriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 270 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 189 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 105 | 20 |
| Mirtazapine | Mirtazapine | 83 | 15 |
| Sertraline Hcl | Sertraline Hcl | 79 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 12 |
| Furosemide | Furosemide | 62 | 12 |
| Prednisone | Prednisone | 61 | 17 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 58 | 11 |
| Metformin Hcl | Metformin Hcl | 54 | suppressed |
| Famotidine | Famotidine | 52 | suppressed |
| Gabapentin | Gabapentin | 52 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Losartan Potassium | Losartan Potassium | 46 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Amantadine | Amantadine Hcl | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Tecentriq | Atezolizumab | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosp/Pf | 23 | suppressed |
| Firmagon | Degarelix Acetate | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Hydroxyurea | Hydroxyurea | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 13 |
| Lisinopril | Lisinopril | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | 11 |
| Torsemide | Torsemide | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Xtandi | Enzalutamide | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Palonosetron Hcl | Palonosetron Hcl | 17 | suppressed |
| Xgeva | Denosumab | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Udenyca | Pegfilgrastim-Cbqv | 14 | suppressed |
| Fosaprepitant Dimeglumine | Fosaprepitant Dimeglumine | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Imbruvica | Ibrutinib | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 11 | suppressed |
| Carboplatin | Carboplatin | 11 | suppressed |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Somatuline Depot | Lanreotide Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $725.67 · 42 records | AstraZeneca Pharmaceuticals LP | BESREMI, BRUKINSA, CARVYKTI, ELAHERE, ENHERTU, EPKINLY, IMBRUVICA, Itovebi, JAKAFI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LYNPARZA, NERLYNX, OPDIVO, PLUVICTO, RYTELO, SARCLISA, SCEMBLIX, Trodelvy, XPOVIO, clonoSEQ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Imbruvica play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error